Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)

Frank L. Meyskens; Joth Jacobson; Bichlien Nguyen; Geoffrey R. Weiss; David R Gandara; John S. MacDonald

doi:10.1023/A:1006032706362

Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)

Frank L. Meyskens, Joth Jacobson, Bichlien Nguyen, Geoffrey R. Weiss, David R Gandara, John S. MacDonald

Hematology and Oncology

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Twenty-nine chemotherapy-naive patients with primary hepatocellular carcinoma were treated with oral β-all transretinoic acid (retinoic acid, TRA 50 mg/m² tid) on a 3-week on/one week off schedule until progression or grade 3 or 4 toxicity. Eligibility requirements allowed abnormal liver function tests as long as the creatinine and bilirubin levels were normal. No responses were seen and the median survival was four months. Grade 3 side effects occurred in 11 patients and grade 4 in four and included a wide range of toxicities. The results indicate that oral TRA is ineffective against primary hepatocellular carcinoma and suggest that dose-modification of this retinoid may be required in patients with significant malignant hepatic involvement.

Original language	English (US)
Pages (from-to)	171-173
Number of pages	3
Journal	Investigational New Drugs
Volume	16
Issue number	2
DOIs	https://doi.org/10.1023/A:1006032706362
State	Published - 1998

Keywords

Hepatocellular carcinoma
Hepatoma
Retinoic acid
Vitamin A

ASJC Scopus subject areas

Molecular Medicine
Pharmacology

Access to Document

10.1023/A:1006032706362

Fingerprint Dive into the research topics of 'Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)'. Together they form a unique fingerprint.

Cite this

@article{34af5865243147089b74e1710046dc25,

title = "Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)",

abstract = "Twenty-nine chemotherapy-naive patients with primary hepatocellular carcinoma were treated with oral β-all transretinoic acid (retinoic acid, TRA 50 mg/m2 tid) on a 3-week on/one week off schedule until progression or grade 3 or 4 toxicity. Eligibility requirements allowed abnormal liver function tests as long as the creatinine and bilirubin levels were normal. No responses were seen and the median survival was four months. Grade 3 side effects occurred in 11 patients and grade 4 in four and included a wide range of toxicities. The results indicate that oral TRA is ineffective against primary hepatocellular carcinoma and suggest that dose-modification of this retinoid may be required in patients with significant malignant hepatic involvement.",

keywords = "Hepatocellular carcinoma, Hepatoma, Retinoic acid, Vitamin A",

author = "Meyskens, {Frank L.} and Joth Jacobson and Bichlien Nguyen and Weiss, {Geoffrey R.} and Gandara, {David R} and MacDonald, {John S.}",

year = "1998",

doi = "10.1023/A:1006032706362",

language = "English (US)",

volume = "16",

pages = "171--173",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)

AU - Meyskens, Frank L.

AU - Jacobson, Joth

AU - Nguyen, Bichlien

AU - Weiss, Geoffrey R.

AU - Gandara, David R

AU - MacDonald, John S.

PY - 1998

Y1 - 1998

N2 - Twenty-nine chemotherapy-naive patients with primary hepatocellular carcinoma were treated with oral β-all transretinoic acid (retinoic acid, TRA 50 mg/m2 tid) on a 3-week on/one week off schedule until progression or grade 3 or 4 toxicity. Eligibility requirements allowed abnormal liver function tests as long as the creatinine and bilirubin levels were normal. No responses were seen and the median survival was four months. Grade 3 side effects occurred in 11 patients and grade 4 in four and included a wide range of toxicities. The results indicate that oral TRA is ineffective against primary hepatocellular carcinoma and suggest that dose-modification of this retinoid may be required in patients with significant malignant hepatic involvement.

AB - Twenty-nine chemotherapy-naive patients with primary hepatocellular carcinoma were treated with oral β-all transretinoic acid (retinoic acid, TRA 50 mg/m2 tid) on a 3-week on/one week off schedule until progression or grade 3 or 4 toxicity. Eligibility requirements allowed abnormal liver function tests as long as the creatinine and bilirubin levels were normal. No responses were seen and the median survival was four months. Grade 3 side effects occurred in 11 patients and grade 4 in four and included a wide range of toxicities. The results indicate that oral TRA is ineffective against primary hepatocellular carcinoma and suggest that dose-modification of this retinoid may be required in patients with significant malignant hepatic involvement.

KW - Hepatocellular carcinoma

KW - Hepatoma

KW - Retinoic acid

KW - Vitamin A

UR - http://www.scopus.com/inward/record.url?scp=7844242539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7844242539&partnerID=8YFLogxK

U2 - 10.1023/A:1006032706362

DO - 10.1023/A:1006032706362

M3 - Article

C2 - 9848581

AN - SCOPUS:7844242539

VL - 16

SP - 171

EP - 173

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -

Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this